Baxter Issues Recall Due to Particulate Matter - - BioPharm International

ADVERTISEMENT

Baxter Issues Recall Due to Particulate Matter


Baxter Healthcare Corp. has initiated a nationwide recall of more than 20,000 containers of Brevibloc Premixed Injection, esmolol hydrochloride in sodium chloride due to the presence of particulate matter.

According to FDA’s July 9 enforcement report, Baxter received complaints of discolored solution identified as subvisible particles of iron oxide that are agglomerating. Baxter issued the recall voluntarily on June 16, 2014.

The recall involved 2,500 mg/250 mL (10 mg/mL), 250 mL Single Use IntraVia container, packaged in 10 x 250 mL Single Use IntraVia containers per carton.

Source: FDA

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Mylan to Acquire Abbott's Non-US Businesses in $5.3 Billion Stock Deal
July 14, 2014
Shire and AbbVie Discuss Possible Deal
July 14, 2014
Author Guidelines

Click here